Stamford, CT -- (SBWIRE) -- 10/05/2013 -- OTC Stock Picks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: Barnes & Noble, Inc. (NYSE:BKS), D.R. Horton, Inc. (NYSE:DHI), HCP, Inc. (NYSE:HCP), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)
Barnes & Noble, Inc. (NYSE:BKS) experienced an upsurge of +10.17%, to a market valuation of $862.41 million per share for the previous trading session. After opening the day at $13.10 per share, volume surged to 2.70 million, moving forward from its daily average volume of 1.41 million shares. Beta value for the Company stands at 1.10, indicating its risk level. The stock remained in the $13.04 to $14.46 price range during the session.
Company’s graphical value indicates these stories about the stocks: During the last 5 trades the stock jumped almost +10.51%. During the last one month it rose with the percentage of +7.3. Its year to date performance remained adverse -4.51%. Barnes & Noble, Inc. operates as a content, commerce, and technology company in the United States. The company operates in three segments: B&N Retail, B&N College, and NOOK.
For How Long BKS’s Gloss will Attract Investors? Find out via this report
D.R. Horton, Inc. (NYSE:DHI) opened its shares at the price of $19.08 for the day, its closing price was $18.54 after losing -2.78% for the day. The company traded with the total volume of 8.11 million shares, while its average trading volume remained 7.48 million shares. The beta of DHI stands at 1.32.
If we review the company’s graph to check its previous trends, we come to know these figures: During the last 5 trades the stock plummeted almost -7.25%. During the last one month it slipped/ rose with the percentage of +3.98. Along with these, its year to date performance remained adverse -6.27%. D.R. Horton, Inc. operates as a homebuilding company. The company engages in the acquisition and development of land; and construction and sale of residential homes in 26 states and 77 markets in the United States primarily under the D.R. Horton, America?s Builder name. It builds traditional single-family detached homes; and attached homes, such as town homes, duplexes, triplexes, and condominiums.
Has DHI Found The Bottom And Ready To Gain Momentum? Find Out Here
HCP, Inc. (NYSE:HCP) percentage change reduced -1.93%, to close at $39.05 with the total traded volume of 7.79 million shares, more than average volume of 2.68 million.
Company’s year to date performance declining as it lost almost -13.53%. If we look at the last 6 months of trade, that is in the bearish zone with a drop of -23.28%.
The 52-week price range of the stock remained $38.58 - $56.06, while during last trade its minimum price was $38.58 and it gained its highest price of 39.93. HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. It primarily invests in properties serving the healthcare industry including sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing.
Why Should Investors Buy HCP After the Recent Fall? Just Go Here and Find Out
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) remained among the day gainers and traded with volume of 2.14million shares in the last session, as compared to average volume of 776,605 shares.
ZIOP was a gainer in the 5 days activity and jumped about +47.17%. The one month performance of the stock was positive and it scored more than +56%.
Its day's lowest price was $2.14 and its hit its day's highest price at $ 776,605. ZIOP’s total market capitalization is $390.89 million along with 83.52 million shares outstanding. ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a DNA alkylating agent, is under Phase III clinical trial for the treatment of first-line metastatic soft tissue sarcoma; and is in Phase III clinical trial for first-line metastatic small cell lung cancer.
Why Should Investors Buy ZIOP After The Recent Gain? Just Go Here and Find Out
About OTC Stock Picks
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)